![Nancy Miller-Rich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nancy Miller-Rich
Direktor/Vorstandsmitglied bei
ALDEYRA THERAPEUTICS, INC.
Vermögen: 1 420 $ am 31.07.2026
Profil
Nancy Miller-Rich is the founder of Miller-Rich Associates LLC, founded in 2017, where the title held is Chief Executive Officer.
Ms. Miller-Rich is the founder of Ten63 Therapeutics, Inc., founded in 2020, with no titles listed.
Current jobs include Executive Chairman at MedMelior, Inc.; Independent Director at Attralus, Inc. since 2020; Director at Global Alliance for TB Drug Development since 2018; Independent Director at Aldeyra Therapeutics, Inc. since 2020; Independent Director at 4D Molecular Therapeutics, Inc. since 2020; and Director at Helio Vision, Inc. Former jobs include Chairman at BioTheryX, Inc. from 2022 to 2023; Independent Director at Intercept Pharmaceuticals, Inc. from 2018 to 2023; Independent Non-Executive Director at UDG Healthcare Ltd. (Dublin) from 2016 to 2020; Independent Director at Kadmon Holdings, Inc. from 2020 to 2021; SVP-Global Human Health Business Development at Merck & Co., Inc. from 2013 to 2017; and SVP-Global Human Health Business Development at Schering-Plough Corp.
USA. from 2013 to 2017.
Education includes an undergraduate degree from Ithaca College conferred in 1981.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.06.2026 | 922 ( 0 % ) | 1 420 $ | 31.07.2026 | |
| 17.06.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
Aktive Positionen von Nancy Miller-Rich
| Unternehmen | Position | Beginn |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 13.01.2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 18.11.2020 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Direktor/Vorstandsmitglied | 06.03.2018 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Vorsitzender | - |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Direktor/Vorstandsmitglied | 01.07.2020 |
Miller-Rich Associates LLC | Vorstandsvorsitzender | 01.01.2017 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Nancy Miller-Rich
| Unternehmen | Position | Ende |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 08.11.2023 |
BioTheryX, Inc.
 BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Vorsitzender | 01.04.2023 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Nancy Miller-Rich
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
92
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Health Technology |
Aldeyra Therapeutics, Inc.
 Aldeyra Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for eye diseases | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Technology Services |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Discovers, develops and delivers transformative therapies for unmet medical needs | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services Provides healthcare advisory, communications, commercial, clinical and packaging services | Commercial Services |
Ithaca College
 Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Health Technology |
TEN63 Therapeutics
 TEN63 Therapeutics Packaged SoftwareTechnology Services Develops AI platform for drug discovery | Technology Services |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Miller-Rich Associates LLC |
